VIVA Biotech H1 profit falls on weaker investment income, FX headwinds

VIVA Biotech Holdings

26/08/2026 11:34

Overview
China-based biopharma services provider's H1 revenue rose 21% yr/yr, driven by CDMO business
Net profit and adjusted non-IFRS net profit fell from prior year
Profit decline attributed to lower investment income, FX movements, and higher R&D costs

Outlook
Company expects CRO revenue growth to regain momentum in the near term, with new modalities and AI technologies as key growth drivers
VIVA Biotech anticipates positive growth trajectory over the medium to long term

Result Drivers
CDMO CONTRIBUTION - Revenue growth was mainly driven by significant contributions from Langhua Pharmaceutical’s CDMO business, including commercial projects entering production phases
LOWER INVESTMENT INCOME AND FX - Decline in net profit was mainly due to a decrease in investment income and unfavorable foreign exchange movements
R&D AND INVESTMENT PRESSURE – Net profit fell to RMB100.9 mln as AI-platform R&D spending rose 41.5% and fair-value gains on incubation investments declined

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.007 bln
 
H1 Net Income Attributable
 
RMB 80.10 mln
 

Analyst Coverage
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 25 - WuXi Biologics H1 net profit up on margin expansion
Aug 24 - Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition
Aug 24 - China's Asymchem H1 revenue rises on strength in emerging businesses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)